ZA978133B - Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride - Google Patents

Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride

Info

Publication number
ZA978133B
ZA978133B ZA978133A ZA978133A ZA978133B ZA 978133 B ZA978133 B ZA 978133B ZA 978133 A ZA978133 A ZA 978133A ZA 978133 A ZA978133 A ZA 978133A ZA 978133 B ZA978133 B ZA 978133B
Authority
ZA
South Africa
Prior art keywords
alpha
methoxyimino
azabicyclo
oct
dosage form
Prior art date
Application number
ZA978133A
Other languages
English (en)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of ZA978133B publication Critical patent/ZA978133B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ZA978133A 1996-09-12 1997-09-10 Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride ZA978133B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
ZA978133B true ZA978133B (en) 1999-04-12

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA978133A ZA978133B (en) 1996-09-12 1997-09-10 Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (id)
JP (1) JP2001500150A (id)
KR (1) KR20000036039A (id)
CN (2) CN1235544A (id)
AR (1) AR008176A1 (id)
AU (1) AU724086B2 (id)
BR (1) BR9711734A (id)
CA (1) CA2265661A1 (id)
CO (1) CO5031291A1 (id)
CZ (1) CZ83299A3 (id)
GB (1) GB9619074D0 (id)
HU (1) HUP9904401A3 (id)
ID (1) ID19589A (id)
IL (1) IL128781A0 (id)
MA (1) MA24359A1 (id)
NO (1) NO991194L (id)
NZ (1) NZ334268A (id)
PE (1) PE2499A1 (id)
PL (1) PL332074A1 (id)
TR (1) TR199900505T2 (id)
WO (1) WO1998010762A2 (id)
ZA (1) ZA978133B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
AU748396C (en) * 1998-03-11 2003-01-23 Smithkline Beecham Corporation Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
EP1628642B2 (en) * 2003-05-14 2013-01-23 Aptalis Pharma Limited Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803B1 (en) * 1989-04-13 2004-06-16 Beecham Group p.l.c. Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
BR9711734A (pt) 1999-08-24
ID19589A (id) 1998-07-23
CO5031291A1 (es) 2001-04-27
EP0929301A2 (en) 1999-07-21
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
CN1235544A (zh) 1999-11-17
TR199900505T2 (id) 1999-06-21
PL332074A1 (en) 1999-08-30
CN1446535A (zh) 2003-10-08
NO991194D0 (no) 1999-03-11
AR008176A1 (es) 1999-12-09
CZ83299A3 (cs) 1999-08-11
HUP9904401A3 (en) 2001-03-28
KR20000036039A (ko) 2000-06-26
NO991194L (no) 1999-03-11
WO1998010762A3 (en) 1998-06-04
MA24359A1 (fr) 1998-07-01
CA2265661A1 (en) 1998-03-19
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
GB9619074D0 (en) 1996-10-23
WO1998010762A2 (en) 1998-03-19
JP2001500150A (ja) 2001-01-09
AU4128897A (en) 1998-04-02
PE2499A1 (es) 1999-03-24

Similar Documents

Publication Publication Date Title
EG20650A (en) Opioid formulations having extended controlled release
EG24291A (en) Novel form of s-omeprazole
PL331862A1 (en) Tablet featurated by controllable release of alphusozine hydrochloride contained therein
PL352100A1 (en) Antagonists of the beta 2 adrenoreceptor
ZA9880B (en) Table for the controlled release of active agents
PL338563A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
EP1017980A4 (en) METHOD FOR IDENTIFYING PHARMACEUTICALLY ACTIVE COMPOUNDS
ZA978133B (en) Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride
HUP0101043A3 (en) Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation
GB0014805D0 (en) Glassbreaker (2)
HUP0003737A3 (en) New process for the preparation of omeprazole
IL131392A0 (en) Process for the preparation of substituted thiazolidinedione
GB2357758B (en) Process for the preparation of 1,1-cyclopropanedicarboxylic diesters
ZA988397B (en) Process for the preparation of substituted 5,6-dihydro-2H-pyran-2-ones
TW385094U (en) Improvement of the video distributor
ZA9811285B (en) New pharmaceutically active compounds
GB9610474D0 (en) Pharmaceutically active compounds
GB9602667D0 (en) Pharmaceutically active compounds
GB9610892D0 (en) Pharmaceutically active compounds
GB9614386D0 (en) Pharmaceutically active compounds
GB9619122D0 (en) Pharmaceutically active compounds
GB9618487D0 (en) Pharmaceutically active compounds
GB9602668D0 (en) Pharmaceutically active compounds
GB9610499D0 (en) Pharmaceutically active compounds
GB9614385D0 (en) Pharmaceutically active compounds